Management of Opioid Misuse and Opioid Use Disorders Among Youth.

Camille A Robinson, J Deanna Wilson
Author Information
  1. Camille A Robinson: Division of General Pediatrics and Adolescent Medicine, Department of Pediatrics, School of Medicine, Johns Hopkins University, Baltimore, Maryland; and.
  2. J Deanna Wilson: Divisions of General Internal Medicine and Adolescent and Young Adult Medicine, School of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania wilsonjd@pitt.edu.

Abstract

In response to the growing impact of the current opioid public health crisis in the United States on adolescents and young adults, pediatricians have an expanding role in identifying opioid use early, preventing escalation of risky use, reducing opioid-related harms, and delivering effective therapies. Research and expert consensus suggest the use of brief interventions focused on reducing risks associated with ongoing opioid use and using motivational interviewing strategies to engage youth in treatment. Because fatal opioid overdose remains a major cause of opioid-related mortality among youth, delivering overdose education as part of any visit in which a youth endorses opioid use is one evidence-based strategy to decrease the burden of opioid-related mortality. For youth that are injecting opioids, safe injection practices and linkage to needle or syringe exchanges should be considered to reduce complications from injection drug use. It is crucial that youth be offered treatment at the time of diagnosis of an opioid use disorder (OUD), including medications, behavioral interventions, and/or referral to mutual support groups. The 2 medications commonly used for office-based OUD treatment in adolescents are extended-release naltrexone (opioid antagonist) and buprenorphine (partial opioid agonist), although there is a significant treatment gap in prescribing these medications to youth, especially adolescents <18 years of age. Addiction is a pediatric disease that pediatricians and adolescent medicine physicians are uniquely poised to manage, given their expertise in longitudinal, preventive, and family- and patient-centered care. Growing evidence supports the need for integration of OUD treatment into primary care.

References

  1. Subst Abuse Treat Prev Policy. 2016 Nov 29;11(1):38 [PMID: 27894311]
  2. Lancet. 2018 Jan 27;391(10118):309-318 [PMID: 29150198]
  3. J Subst Abuse Treat. 2016 Jan;60:6-13 [PMID: 26233698]
  4. J Fam Ther. 2009 May 1;31(2):126-154 [PMID: 21113237]
  5. Ann Intern Med. 2017 Feb 21;166(4):268-278 [PMID: 27919103]
  6. JAMA Intern Med. 2019 Feb 1;179(2):145-152 [PMID: 30508022]
  7. Subst Abus. 2016;37(1):20-4 [PMID: 26848803]
  8. Addiction. 2004 Nov;99 Suppl 2:76-92 [PMID: 15488107]
  9. BMC Public Health. 2017 Apr 11;17(1):309 [PMID: 28399843]
  10. Int J Drug Policy. 2016 May;31:25-31 [PMID: 26919826]
  11. Drug Alcohol Rev. 2006 Mar;25(2):167-71 [PMID: 16627307]
  12. Arch Pediatr Adolesc Med. 1999 Jun;153(6):591-6 [PMID: 10357299]
  13. Drug Alcohol Depend. 2014 Dec 1;145:48-68 [PMID: 25456324]
  14. Subst Abus. 2016;37(1):197-203 [PMID: 25774878]
  15. J Addict Med. 2014 May-Jun;8(3):153-63 [PMID: 24874759]
  16. Ann Fam Med. 2015 Jan-Feb;13(1):23-6 [PMID: 25583888]
  17. JAMA Netw Open. 2018 Jun 1;1(2):e180217 [PMID: 30646062]
  18. J Subst Abuse Treat. 2016 Jan;60:81-90 [PMID: 26297321]
  19. Curr Opin Pediatr. 2016 Apr;28(2):258-65 [PMID: 26867164]
  20. Harm Reduct J. 2017 Jul 31;14(1):53 [PMID: 28760146]
  21. J Child Adolesc Subst Abuse. 2015;24(3):166-176 [PMID: 25870511]
  22. J Subst Abuse Treat. 2008 Jul;35(1):53-61 [PMID: 18037603]
  23. Addiction. 2007 Aug;102(8):1234-43 [PMID: 17565560]
  24. Inj Epidemiol. 2015 Dec;2(1):10 [PMID: 27747742]
  25. Drug Alcohol Depend. 2016 Jan 1;158:102-9 [PMID: 26651427]
  26. JAMA. 2018 Nov 13;320(18):1910-1928 [PMID: 30422198]
  27. J Subst Abuse Treat. 2015 Apr;51:1-18 [PMID: 25300577]
  28. J Subst Abuse Treat. 2018 Feb;85:84-89 [PMID: 28867062]
  29. Harv Rev Psychiatry. 2015 Mar-Apr;23(2):63-75 [PMID: 25747920]
  30. Addict Behav. 2012 Dec;37(12):1325-34 [PMID: 22958865]
  31. Subst Use Misuse. 2009;44(14):1979-89 [PMID: 20001689]
  32. Subst Abus. 2012;33(4):321-6 [PMID: 22989275]
  33. Addiction. 2016 Aug;111(8):1406-15 [PMID: 26918564]
  34. Psychiatr Serv. 2014 Feb 1;65(2):158-70 [PMID: 24247147]
  35. J Subst Abuse. 2001;13(4):493-504 [PMID: 11775078]
  36. JAMA Intern Med. 2018 Jun 1;178(6):764-773 [PMID: 29799968]
  37. Pediatrics. 2016 Sep;138(3): [PMID: 27550978]
  38. Clin Pediatr (Phila). 2018 Sep;57(10):1232-1235 [PMID: 29256261]
  39. Psychiatr Serv. 2014 Feb 1;65(2):146-57 [PMID: 24248468]
  40. Subst Use Misuse. 2003 Sep-Nov;38(11-13):1759-87 [PMID: 14582577]
  41. PLoS One. 2017 Oct 17;12(10):e0186315 [PMID: 29040331]
  42. Lancet. 2011 Apr 23;377(9775):1429-37 [PMID: 21497898]
  43. Pediatrics. 2004 Nov;114(5):e536-40 [PMID: 15520086]
  44. Lancet. 2019 Feb 23;393(10173):778-790 [PMID: 30792007]
  45. JAMA Pediatr. 2017 Aug 1;171(8):747-755 [PMID: 28628701]
  46. J Subst Abuse Treat. 2017 May;76:20-27 [PMID: 28340904]
  47. Pediatr Rev. 2018 Jan;39(1):43-45 [PMID: 29292291]
  48. JAMA Pediatr. 2018 Nov 1;172(11):1029-1037 [PMID: 30208470]
  49. J Addict Med. 2014 May-Jun;8(3):176-82 [PMID: 24695018]
  50. Pediatrics. 2017 Apr;139(4): [PMID: 28320868]
  51. J Adolesc Health. 2017 Mar;60(3):261-269 [PMID: 28087267]
  52. Lancet. 2016 Sep 24;388(10051):1260-1 [PMID: 27673455]
  53. Curr Pediatr Rep. 2018 Jun;6(2):99-106 [PMID: 30895165]
  54. Pediatrics. 2014 May;133(5):819-26 [PMID: 24753528]
  55. Ann Intern Med. 2018 Aug 7;169(3):137-145 [PMID: 29913516]
  56. J Addict Med. 2018 May/Jun;12(3):170-183 [PMID: 29432333]
  57. JAMA Psychiatry. 2014 Jul 1;71(7):821-6 [PMID: 24871348]
  58. Arch Gen Psychiatry. 2005 Oct;62(10):1157-64 [PMID: 16203961]
  59. J Subst Abuse Treat. 2015 Jan;48(1):13-20 [PMID: 25124258]
  60. Alcohol Clin Exp Res. 2013 Oct;37(10):1753-62 [PMID: 23802878]
  61. Alcohol Clin Exp Res. 2012 Jul;36(7):1219-29 [PMID: 22509904]
  62. Pediatrics. 2012 Jun;129(6):1072-82 [PMID: 22566420]
  63. JAMA. 2008 Nov 5;300(17):2003-11 [PMID: 18984887]
  64. J Subst Abuse Treat. 2016 Mar;62:28-37 [PMID: 26742723]
  65. Child Adolesc Psychiatr Clin N Am. 2010 Jul;19(3):547-62 [PMID: 20682220]
  66. MMWR Surveill Summ. 2018 Jun 15;67(8):1-114 [PMID: 29902162]
  67. Cochrane Database Syst Rev. 2014 Feb 06;(2):CD002207 [PMID: 24500948]
  68. Int J Addict. 1973;8(5):853-63 [PMID: 4781422]
  69. Am J Public Health. 2009 Mar;99(3):402-7 [PMID: 19150908]
  70. Int J Drug Policy. 2015 Jan;26(1):84-91 [PMID: 25151334]
  71. J Addict Dis. 2012;31(3):207-25 [PMID: 22873183]
  72. Am J Prev Med. 2018 Jun;54(6 Suppl 3):S275-S280 [PMID: 29779552]
  73. Alcohol Clin Exp Res. 2012 Mar;36(3):552-60 [PMID: 22168137]
  74. Drug Alcohol Depend. 2015 Mar 1;148:209-12 [PMID: 25595053]
  75. J Addict Med. 2017 Jul/Aug;11(4):286-292 [PMID: 28379862]
  76. J Adolesc Health. 2017 Jun;60(6):747-750 [PMID: 28258807]
  77. JAMA. 2018 Nov 13;320(18):1899-1909 [PMID: 30422199]
  78. Addiction. 2010 Sep;105(9):1669-76 [PMID: 20626723]
  79. J Subst Abuse Treat. 2004 Oct;27(3):197-213 [PMID: 15501373]
  80. Child Adolesc Psychiatr Clin N Am. 2016 Oct;25(4):685-711 [PMID: 27613346]
  81. Arch Intern Med. 2011 Mar 14;171(5):425-31 [PMID: 21403039]
  82. Pediatrics. 2016 Jul;138(1): [PMID: 27325634]
  83. JAMA Pediatr. 2014 Sep;168(9):822-8 [PMID: 25070067]

Grants

  1. T32 HD052459/NICHD NIH HHS

MeSH Term

Adolescent
Adolescent Medicine
Behavior Therapy
Buprenorphine
Cause of Death
Combined Modality Therapy
Cross-Sectional Studies
Delayed-Action Preparations
Female
Humans
Male
Naltrexone
Opioid-Related Disorders
Pediatrics
Self-Help Groups
Substance Abuse, Intravenous
United States
Young Adult

Chemicals

Delayed-Action Preparations
Buprenorphine
Naltrexone

Word Cloud

Created with Highcharts 10.0.0opioiduseyouthtreatmentadolescentsopioid-relatedOUDmedicationspediatriciansreducingdeliveringinterventionsoverdosemortalityinjectioncareOpioidresponsegrowingimpactcurrentpublichealthcrisisUnitedStatesyoungadultsexpandingroleidentifyingearlypreventingescalationriskyharmseffectivetherapiesResearchexpertconsensussuggestbrieffocusedrisksassociatedongoingusingmotivationalinterviewingstrategiesengagefatalremainsmajorcauseamongeducationpartvisitendorsesoneevidence-basedstrategydecreaseburdeninjectingopioidssafepracticeslinkageneedlesyringeexchangesconsideredreducecomplicationsdrugcrucialofferedtimediagnosisdisorderincludingbehavioraland/orreferralmutualsupportgroups2commonlyusedoffice-basedextended-releasenaltrexoneantagonistbuprenorphinepartialagonistalthoughsignificantgapprescribingespecially<18yearsageAddictionpediatricdiseaseadolescentmedicinephysiciansuniquelypoisedmanagegivenexpertiselongitudinalpreventivefamily-patient-centeredGrowingevidencesupportsneedintegrationprimaryManagementMisuseUseDisordersAmongYouth

Similar Articles

Cited By